BACKGROUND

Enterococcal species, particularly E. faecalis and E. faecium, are the second most common cause of Gram-positive blood stream infection globally, following Staphylococcus aureus. Despite this high prevalence, enterococcal bacteremia is associated with a 20-30% all-cause 30-day mortality rate, and a high risk of endocarditis. Although combination antibiotic therapy is generally used for enterococcal endocarditis, the data to support this practice are weak and conflicting and there have been no previous RCTs. The same applies to the choice of backbone antibiotic, the duration of therapy, and other aspects of management.

As an expansion of the SNAP (S.aureus platform trial) and STRAP (Streptotoccal platform trial) program of work, we are planning an international multi-domain adaptive platform randomised trial to determine the most effective management of enterococcal bacteraemia and endocarditis. This type of trial can address multiple questions simultaneously, and we want your input to help prioritise which questions to put into the platform.

If you are not a practicing clinician in a field relevant to enterococcal bacteraemia or endocarditis, please do not answer the survey. At this stage we are only planning to enrol adult patients, so if you are a paedatrician please don't answer the survey.

Thank you for taking this survey it should take less than 10 minutes. Your consent as a survey participant is implied if you fill it out.

We need you and your site as part of our study team to make this a success!

Australia leads
  • Prof Josh Davis - Joshua.Davis@health.nsw.gov.au
  • Prof Steven Tong
Canada leads
  • Prof Todd Lee - todd.lee@mcgill.ca
  • A/Prof Emily McDonald
UK leads
  • Prof Anna Goodman - anna.goodman@nhs.net
  • Prof Michael Marks
NZ leads
  • Dr Genevieve Walls - genevieve.walls@middlemore.co.nz
  • Dr Simon Briggs
Asia leads
  • Dr YuChung Chuang - weischuang@gmail.com
  • Prof David Paterson

For the TENT investigators

T